Journal of Clinical Oncology (JCO) Podcast

This podcast reviews the biology and treatment of relapse of acute myeloid leukemia following hematopoietic transplantation.

The ability of an advance care planning discussion to affect end-of-life decisions is tested in a randomized, controlled trial of patients with advanced cancer.

The AVAPERL trial reveals a significant improvement in progression-free survival with the combination of pemetrexed/bevacizumab compared with bevacizumab alone as maintenance therapy for advanced non- small-cell lung cancer, but the clinically relevant endpoint remains overall survival.

This JCO Podcast provides observations and commentary on the JCO article "Osteonecrosis of the Jaw and Oral Health-Related Quality of Life After Adjuvant Zoledronic Acid: An Adjuvant Zoledronic Acid to Reduce Recurrence Trial Subprotocol (BIG01/04)" by Emma Rathbone et al.

Minimal residual disease predicts outcomes in myeloma.

This podcast provides an overview and commentary on Amant et al.'s study of breast cancer diagnosed during pregnancy.

This podcast provides observations and commentary on the JCO article,"Results of an international randomized phase 3 trial of the mTOR inhibitor, ridaforolimus, versus placebo to control metastatic sarcomas in patients following benefit from prior chemotherapy" by authors George Demetri, et al.

Loss of PTEN expression did not predict resistance to trastuzumab in early stage HER2 positive breast cancer in the large US cooperative group phase III trial N9831.

This podcast describes the current and future use of molecular testing, including micro RNA expression, in the management of AML.

This podcast focuses on emerging concerns about adult outcomes in survivors of acute lymphoblastic leukemia treated in childhood and adolescence in the context of the report by Zeller and colleagues documenting neuroanatomical and neuropsychological impairment in a large sample of adults treated successfully for ALL without cranial radiation therapy and healthy controls.

This Podcast reviews the results of the analysis conducted by Metzger-Filho et al. regarding the benefit of trastuzumab for patients with invasive lobular breast cancer treated on the Herceptin Adjuvant Trial (HERA) and provides perspective regarding the clinical significance of these findings.

This podcast summarizes findings regarding cigarette smoking and disease-free survival in a Phase III adjuvant colon cancer trial.

Response after early chemotherapy cycles might identify patients who could safely forgo consolidation with radiotherapy.

This podcast reflects on the outcome of minimal intensity conditioning in over 1000 recipients of sibling and unrelated donor transplant.

This podcast provides commentary and observations on the long term results summary of RTOG 91-11 in which concurrent chemoradiation was shown to provide superior outcome over induction chemotherapy or radiation alone to achieve larynx preservation and locoregional tumor control.

This podcast reviews findings on the prevalence of off-label cancer therapy use and the estimated costs associated with it.

If transplantation is selected as the treatment approach, the net effect is likely to be similar with allogeneic or autologous transplantation with the higher early mortality rate in the allogeneic patients offset by a higher relapse rate in the autologous patients.

The fluoroquinolone class of antibiotics is a major target for antimicrobial stewardship programs, and the conservation of their effectiveness is important.

This podcast provides perspective on findings in a large population-based evaluation of overall survival and cancer-specific survival in patients with CLL who develop a second primary cancer.

One third of gastric cancers harbor genetic or epigenetic alterations in the CDH1 gene, and those with structural changes have a poorer prognosis; gastric tumor profiling for oncogenic amplifications and mutations may identify targets for personalized therapeutics.

This podcast considers the evolution, utility, and acceptability of the terms 'cancer survivor' and 'cancer survivorship' and comments on a recent article in JCO that addresses the extent to which such labels matter to survivors and others affected by this disease.

This podcast discusses approaches to risk assessment of contralateral breast cancer and factors which predict the risk.

Amongst several different liver directed therapy approaches, chemoembolization (called TACE) and radiofrequency ablation (called RFA) are most commonly used worldwide. However, the efficacy of TACE and RFA remains limited.

A discussion of a phase 2 trial of a MEK inhibitor in patients with V600 BRAF mutations and consideration of other relevant results with targeted therapies in this population.

This podcast discusses therapeutic options for MDS patients including azacytidine and allogeneic stem cell transplantation.